BioSapien, the pioneering biotech company behind the MediChip™ — a breakthrough localized cancer treatment platform — has announced an extension of its pre-Series A funding round and a series of key leadership appointments across the organization.
The Company is proud to welcome Globivest, the first women-led, gender lens venture capital fund from the MENA region, as a new investor. With deep expertise in Life Sciences and a mission to align capital returns with impact-driven outcomes, Globivest represents an ideal strategic partner for BioSapien. Their investment brings BioSapien’s total pre-Series A funding to over $8 million, with participation from notable investors including Global Ventures, Golden Gate Ventures, and Dara Holdings.
Championing the WHO’s “One Health” vision, Globivest backs early-stage startups that create scalable solutions across health, environmental, and social domains — making BioSapien and its MediChip™ platform a natural fit for its portfolio.
To support the next phase of growth, BioSapien is also announcing 12 new appointments, strengthening its capabilities across science, regulatory, manufacturing, and business functions. Notable leadership hires include:
Joseph Borrello, PhD – Chief Technology Officer
Sonia Ramamoorthy, MD MBA FACS – Head of Medical Affairs
Agnes Westelinck, PharmD – Head of U.S. Regulatory
Dirk Richter, MD FACS – Head of Regulatory, U.A.E.
David Briere, PhD – Director of Pharmacology
Jerry Webb, BSc – Head of Quality
Additional key team members joining BioSapien include:
Zhiyu Xia, PhD – Senior Manufacturing Engineer
Gaurav Vij, MBA – Business Officer
Nancy Sperling, MS MS – QC Lead
Nivedita Sivakumar, PharmD MS – Documentation and Compliance Manager
Manny Valenza, BA – Clinical Development Associate
Jared Rice, BA – Research and Operations Lead
Dr. Khatija Ali, CEO of BioSapien, stated:
“Two of the biggest challenges for high-growth startups are building a strong financial foundation and attracting exceptional talent. With the extended support of globally-minded investors like Globivest — and the addition of such accomplished professionals — BioSapien is uniquely positioned to scale its vision. We are thrilled to grow a team that reflects our values of excellence, diversity, and impact. Together, we are shaping a future where precision medicine is not only innovative but also widely accessible.”
Dr. Laura-Joy Boulos, Partner at Globivest, added:
“At Globivest, we invest in companies that don’t just innovate — they redefine what’s possible in science and healthcare. BioSapien’s MediChip™ technology is exactly that: a disruptive, scalable platform that advances localized cancer care. We are proud to support Dr. Ali and her team as they lead the charge in accessible, science-driven precision medicine.”